Chinese researchers have made a groundbreaking discovery in the field of immunology and aging, identifying the transcription factor RUNX1 (Runt-related transcription factor 1) as a pivotal regulator that slows the aging process in T cells, the frontline warriors of the adaptive immune system. This finding, detailed in a study published in the prestigious journal Immunity, emerges from collaborative efforts between the China National Center for Bioinformation, the Institute of Zoology under the Chinese Academy of Sciences (CAS), and Quzhou Affiliated Hospital of Wenzhou Medical University. By developing the Human Immune Aging Clock (HIAC), a precise tool to quantify immune system age, the team has not only mapped the dynamics of immune senescence but also pinpointed actionable targets for interventions that could rejuvenate aging immunity.
As China's population rapidly ages—with over 300 million individuals aged 60 and above as of 2025—these advancements hold profound implications for public health, vaccine efficacy, and chronic disease management. T cells, or T lymphocytes, are essential for recognizing and destroying pathogens and cancer cells. With age, naive T cells—those yet to encounter specific antigens—dwindle, while exhausted T cells accumulate, leading to weakened responses to infections and reduced vaccine effectiveness. This study illuminates why this happens and offers hope for reversal.
The Challenge of Immune Aging in Modern China
Immune aging, or immunosenescence, contributes significantly to age-related vulnerabilities. In China, where life expectancy has climbed to 78.6 years, the elderly face heightened risks from respiratory infections, cancer, and autoimmune disorders. Statistics from the National Health Commission indicate that individuals over 65 account for 40% of severe COVID-19 cases despite comprising 14% of the population, underscoring impaired T cell function.
Traditional metrics like chronological age fail to capture biological immune decline, which varies widely. Factors such as lifestyle, environment, and genetics influence this process. Researchers at CAS institutes recognized this gap, leveraging China's vast cohort studies and advanced single-cell technologies to pioneer quantitative assessment. Wenzhou Medical University, through its Quzhou affiliate, contributed clinical samples, bridging basic research with translational medicine—a hallmark of China's integrated higher education-research ecosystem.
- Decline in naive CD4+ and CD8+ T cells by up to 50% post-40 years.
- Increase in terminally differentiated effector T cells, linked to chronic inflammation (inflammaging).
- Reduced thymic output, shrinking the T cell repertoire diversity.
Unveiling the Human Immune Aging Clock
The cornerstone of this research is the HIAC, constructed from single-cell multi-omics profiling of nearly 1.2 million peripheral blood mononuclear cells (PBMCs) from 230 healthy donors spanning ages 20 to 90. Using transcriptomics, proteomics, and epigenomics, the team delineated 24 immune cell subtypes, with T cells emerging as the most sensitive barometer of aging.
HIAC predicts biological immune age with remarkable accuracy—an average error of just 5.66 years—outperforming existing epigenetic clocks. It integrates features like gene expression signatures, clonal expansion, and metabolic shifts. A critical inflection point at around 40 years marks accelerated decline, aligning with midlife health transitions observed in Chinese longitudinal studies like the China Health and Retirement Longitudinal Study (CHARLS).
This tool, validated across independent cohorts, enables personalized immune health monitoring. For higher education, it exemplifies how bioinformatics hubs like CNCI empower multidisciplinary teams, training next-generation immunologists.
T Cells: The Nexus of Immune Senescence
T cells orchestrate adaptive immunity, differentiating into effector subsets upon antigen encounter. Naive T cells constitute the diverse pool ready for novel threats; their loss with age—termed 'memory inflation'—impairs responses to new pathogens like influenza or emerging viruses.
The study revealed profound T cell remodeling: naive subsets plummet, effector memory T cells (TEMRA) surge, and regulatory T cells expand, fostering tolerance over aggression. Monocytes also shift toward pro-inflammatory states. These changes correlate with physiological markers like frailty index and grip strength, linking immune age to overall healthspan.
RUNX1: The Youth-Preserving Guardian
At the molecular heart lies RUNX1, a zinc-finger transcription factor vital for hematopoiesis and T cell development. Its expression wanes progressively in aging T cells, disrupting a pro-youthful gene network that suppresses senescence-associated secretory phenotype (SASP)—pro-inflammatory cytokines driving tissue damage.
CRISPR knockout of RUNX1 in young human T cells induced cell cycle arrest, SASP activation, and telomere shortening hallmarks of senescence. Conversely, lentiviral overexpression in aged CD8+ T cells restored proliferation, cytokine production (IFN-γ, TNF-α), and cytotoxicity. In vivo, RUNX1-overexpressing T cells from old mice cleared Listeria monocytogenes infections more effectively, mimicking youthful vigor.
This bidirectional validation positions RUNX1 as the first endogenous decelerator of T cell aging, opening avenues for gene therapy or small-molecule activators.
For deeper insights, explore the original study in Immunity.
Experimental Rigor and Validation
The multi-omics atlas employed 10x Genomics for scRNA-seq, CITE-seq for surface proteins, and ATAC-seq for chromatin accessibility. Machine learning models, trained on T cell features, achieved 92% accuracy in age prediction.
Functional assays included flow cytometry for senescence markers (p16, SA-β-gal), qPCR for SASP genes (IL-6, IL-8), and killing assays against tumor targets. Mouse chimeras confirmed translational relevance, with RUNX1 boosting survival in infection models.
CAS's state-of-the-art facilities, coupled with UCAS training, underscore China's ascent in single-cell immunology.
Implications for Vaccines and Cancer Immunotherapy
Elderly vaccine responses falter due to naive T cell scarcity; HIAC could stratify patients for boosters. RUNX1 modulation might enhance neoantigen-specific T cells in CAR-T or checkpoint therapies, where exhaustion plagues outcomes.
In China, with 10 million new cancer cases yearly (2025 stats), rejuvenating T cells could amplify PD-1 inhibitors. Preliminary models suggest 20-30% efficacy gains.
- Improved flu/pneumonia vaccine take in over-65s.
- Boosted tumor-infiltrating lymphocytes persistence.
- Reduced post-transplant rejection via balanced regulation.
Read more on clinical potential via CAS report.
China's Vanguard in Aging Research
CAS institutes like IOZ and CNCI lead globally, with the Aging Biomarker Consortium (ABC) fostering multi-omics clocks. Wenzhou Medical University exemplifies provincial contributions, its Quzhou hospital providing real-world cohorts amid Zhejiang's biotech boom.
China invests ¥20 billion annually in longevity (2026 budget), supporting 500+ aging labs. UCAS integrates PhD training, producing 10,000 stem cell/immunology grads yearly. This study reflects 'Double First-Class' initiatives elevating Peking U, Tsinghua alongside CAS.
Challenges and Ethical Horizons
While promising, RUNX1 therapies face delivery hurdles—AAV vectors or CRISPR editing need refinement for safety. Off-target effects in hematopoiesis require vigilant monitoring.
Ethically, equitable access in rural China is paramount. HIAC democratizes screening, but data privacy under GDPR-like laws is crucial.
Future Outlook: Rejuvenation Therapies on Horizon
Pipeline includes RUNX1 agonists from high-throughput screens at CNCI. Clinical trials for immune frailty could launch by 2028, targeting 100 million elderly.
Integration with AI predicts personalized interventions, aligning with 'Healthy China 2030'. Collaborations with global hubs like Cold Spring Harbor amplify impact.
For related career opportunities, explore research positions.